Postinfectious chronic fatigue syndrome: case history of thirty-five patients in Germany.
Hilgers, A, Krueger, G R, Lembke, U et al. · In vivo (Athens, Greece) · 1991
Quick Summary
This study followed 35 ME/CFS patients in Germany for up to eight years and found that most experienced severe fatigue, joint and muscle pain, sore throats, and various other symptoms. Researchers found evidence of herpesvirus reactivation in about 73% of patients and Epstein-Barr virus in about 34%, suggesting ongoing viral activity may play a role in the condition. While treatments were tried including immune therapy and antiviral drugs, none consistently worked well, though immune globulin therapy showed the most promise.
Why It Matters
This study from the early post-CFS-definition era provides evidence linking ME/CFS to persistent or recurrent viral reactivation, particularly HHV-6, which has remained a focus of research. It documents that the condition involves multiple biological systems beyond fatigue alone and highlights why comprehensive, individualized approaches may be necessary rather than one-size-fits-all treatments.
Observed Findings
Severe fatigue, arthralgias, and myalgias were reported by nearly all patients
HHV-6 reactivation/persistence detected in 73% of patients; EBV in 34.4%
More than half of patients experienced neuropathy, lymphadenopathy, gastrointestinal complaints, and recurrent low-grade fever
Variable and inconsistent immunologic abnormalities across the patient group
Immunoglobulin therapy showed modest benefit compared to antivirals and nonspecific immunostimulation
Inferred Conclusions
Chronic viral reactivation, particularly HHV-6, may be associated with ME/CFS pathogenesis
Immune dysregulation is heterogeneous across ME/CFS patients and may not follow a single pattern
Psycho-neuroimmunologic dysfunction may play a significant role in disease maintenance
Current immunologic and antiviral treatments are insufficient for most patients
Remaining Questions
Is HHV-6 reactivation a cause of ME/CFS or a consequence of immune dysregulation?
Why do immunologic abnormalities vary so much between patients—are there distinct ME/CFS subtypes?
What This Study Does Not Prove
This study does not prove that viruses cause ME/CFS, only that they are frequently present in affected individuals—causation remains unclear. The variable immunologic findings and treatment failures mean we cannot conclude what the underlying mechanism is or which treatments definitively work. Small sample size and lack of age/sex-matched controls limit how well these results apply to the broader ME/CFS population.